Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000054.xml
CC BY-NC-ND 4.0 · Pharmacopsychiatry 2022; 55(03): 121-138
DOI: 10.1055/a-1721-2914
DOI: 10.1055/a-1721-2914
Review
Classic Psychedelic Drugs: Update on Biological Mechanisms
Abstract
Renewed interest in the effects of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiological mechanisms underlying the effects of these substances. During the past two decades, state-of-the-art studies of animals and humans have yielded new important insights into the molecular, cellular, and systems-level actions of psychedelic drugs. These efforts have revealed that psychedelics affect primarily serotonergic receptor subtypes located in cortico-thalamic and cortico-cortical feedback circuits of information processing. Psychedelic drugs modulate excitatory-inhibitory balance in these circuits and can participate in neuroplasticity within brain structures critical for the integration of information relevant to sensation, cognition, emotions, and the narrative of self. Neuroimaging studies showed that characteristic dimensions of the psychedelic experience obtained through subjective questionnaires as well as alterations in self-referential processing and emotion regulation obtained through neuropsychological tasks are associated with distinct changes in brain activity and connectivity patterns at multiple-system levels. These recent results suggest that changes in self-experience, emotional processing, and social cognition may contribute to the potential therapeutic effects of psychedelics.
Publication History
Received: 26 May 2021
Received: 08 November 2021
Accepted: 22 November 2021
Article published online:
25 January 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 McKenna D, Riba J. New world tryptamine hallucinogens and the neuroscience of Ayahuasca. Curr Top Behav Neurosci 2018; 36: 283-311 DOI: 10.1007/7854_2016_472.
- 2 Hofmann A, Heim R, Brack A. et al. Psilocybin und psilocin, zwei psychotrope wirkstoffe aus Mexikanischen rauschpilzen. Helv chim Acta 1959; 42: 1557-1572
- 3 Schultes RE, Hofmann A. The botany and chemistry of hallucinogens. 2 edn. Springfield: Charles C. Thomas; 1980
- 4 Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101: 131-181
- 5 Dittrich A, von Arx S, Staub S. International study on altered states of consciousness (ISASC). Summary of the results. Germ J Psych 1985; 9: 319-339
- 6 Preller KH, Vollenweider FX. Phenomenology, structure, and dynamic of psychedelic States. Curr Top Behav Neurosci 2018; 36: 221-256 DOI: 10.1007/7854_2016_459.
- 7 Letheby C, Gerrans P. Self unbound: Ego dissolution in psychedelic experience. Neurosci Conscious 2017; 2017: nix016 DOI: 10.1093/nc/nix016.
- 8 Milliere R. Looking for the self: Phenomenology, neurophysiology and philosophical significance of drug-induced ego dissolution. Front Hum Neurosci 2017; 11: 245 DOI: 10.3389/fnhum.2017.00245.
- 9 Hofmann A. Psychotomimetic Agents. In: Burger A, ed. Chemical constitution and pharmacodynamic actions. 2 edn. New York: M.Dekker; 1968: 169-235
- 10 Rucker JJ, Jelen LA, Flynn S. et al. Psychedelics in the treatment of unipolar mood disorders: A systematic review. J Psychopharmacol 2016; 30: 1220-1229 DOI: 10.1177/0269881116679368.
- 11 Leuner H. Hallucinogens as an Aid in Psychotherapy: Basic Principles and Results. In: Pletscher A, Ladewig D, eds. 50 years of LSD: Current status and perspectives of hallucinogens a symposium the Swiss Academy of Medical Sciences. 1 edn. New York: The Parthenon Publishing Group; 1994: 175-189
- 12 Abuzzahab FS, Anderson BJ. A review of LSD treatment in alcoholism. Int Pharmacopsychiatry 1971; 6: 223-235
- 13 Pletscher A, Ladewig D. 50 Years of LSD: Current Status and Perspectives of Hallucinogens. A Symposium the Swiss Academy of Medical Sciences. New York, London: The Parthenon Publishing Group; 1994
- 14 Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci 2010; 11: 642-651
- 15 Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Babler A. et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 1998; 9: 3897-3902
- 16 Preller KH, Herdener M, Pokorny T. et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol 2017; 27: 451-457 DOI: 10.1016/j.cub.2016.12.030.
- 17 Mason NL, Kuypers KPC, Muller F. et al. Me, myself, bye: Regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology 2020; DOI: 10.1038/s41386-020-0718-8.
- 18 Vollenweider FX, Vontobel P, Hell D. et al. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man - A PET study with [C-11]raclopride. Neuropsychopharmacology 1999; 20: 424-433
- 19 Vollenweider FX, Preller KH. Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci 2020; 21: 611-624 DOI: 10.1038/s41583-020-0367-2.
- 20 Preller KH, Vollenweider FX. Modulation of social cognition via hallucinogens and “Entactogens”. Front Psychiatry 2019; 10: 881 DOI: 10.3389/fpsyt.2019.00881.
- 21 Northoff G, Wiebking C, Feinberg T. et al. The ‘resting-state hypothesis’ of major depressive disorder – a translational subcortical-cortical framework for a system disorder. Neurosci Biobehav Rev 2011; 35: 1929-1945 DOI: 10.1016/j.neubiorev.2010.12.007.
- 22 Disner SG, Beevers CG, Haigh EA. et al. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci 2011; 12: 467-477 DOI: 10.1038/nrn3027.
- 23 Disner SG, Shumake JD, Beevers CG. Self-referential schemas and attentional bias predict severity and naturalistic course of depression symptoms. Cogn Emot 2017; 31: 632-644 DOI: 10.1080/02699931.2016.1146123.
- 24 Brakowski J, Spinelli S, Dorig N. et al. Resting state brain network function in major depression - Depression symptomatology, antidepressant treatment effects, future research. J Psychiatr Res 2017; 92: 147-159 DOI: 10.1016/j.jpsychires.2017.04.007.
- 25 Scalabrini A, Vai B, Poletti S. et al. All roads lead to the default-mode network-global source of DMN abnormalities in major depressive disorder. Neuropsychopharmacology 2020; 45: 2058-2069 DOI: 10.1038/s41386-020-0785-x.
- 26 Banks MI, Zahid Z, Jones NT. et al. Catalysts for change: The cellular neurobiology of psychedelics. Mol Biol Cell 2021; 32: 1135-1144 DOI: 10.1091/mbc.E20-05-0340.
- 27 Dos Santos RG, Hallak JEC. Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. Neurosci Biobehav Rev 2020; 108: 423-434 DOI: 10.1016/j.neubiorev.2019.12.001.
- 28 Wozniak M. “I” and “Me”: The self in the context of consciousness. Front Psychol 2018; 9: 1656 DOI: 10.3389/fpsyg.2018.01656.
- 29 Metzinger T. The ego tunnel. The science of the mind and the myth of the self. 1 edn. New York: Basic Books; 2009
- 30 Studerus E. Psilocybin-Induced Altered States of Consciousness. Tolerability, Assessment, and Prediction. Südwestdeutscher Verlag für Hochschulschriften 2013; 1-180 . ISBN 978-3-8381-3663-9
- 31 Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 2010; 5: e12412
- 32 Studerus E, Gamma A, Kometer M. et al. Prediction of psilocybin response in healthy volunteers. Plos One 2012; 7: e30800
- 33 Griffiths RR, Johnson MW, Richards WA. et al. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology (Berl) 2011; 218: 649-665 DOI: 10.1007/s00213-011-2358-5.
- 34 Schmid Y, Enzler F, Gasser P. et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry 2015; 78: 544-553
- 35 Dolder PC, Schmid Y, Steuer AE. et al. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinet 2017; 56: 1219-1230 DOI: 10.1007/s40262-017-0513-9.
- 36 Holze F, Vizeli P, Ley L. et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 2021; 46: 537-544 DOI: 10.1038/s41386-020-00883-6.
- 37 Dambrun M, Ricard M. Self-centeredness and selflessness: A theory of self-based psychological functioning and its consequences for happiness. Rev Gen Psychol 2011; 15: 138-157 DOI: 10.1037/a0023059.
- 38 Stace WT. Mysticism and philosophy. 1 edn. London: Macmillan; 1961
- 39 Hood RW. Theory and methods in the psychological study of mysticism. Int J Psychol Relig 2013; 23: 294-306 DOI: 10.1080/10508619.2013.795803.
- 40 Yaden DB, Le Nguyen KD, Kern ML. et al. Of roots and fruits: A comparison of psychedelic and nonpsychedelic mystical experiences. J Humanist Psychol 2017; 57: 338-353 DOI: 10.1177/0022167816674625.
- 41 Leuner H. Halluzinogene. Psychische grenzzustände in forschung und therapie. 1 edn. Bern: Hans Huber; 1981
- 42 Leuner H. Die experimentelle psychose. 1 edn. Berlin: Springer; 1962
- 43 Leuner H, Holfeld H. Results and problems of psychotherapy with adjuvant LSD-25 and related substances. Psychiatr Neurol (Basel) 1962; 143: 379-391
- 44 Griffiths RR, Richards WA, McCann U. et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 2006; 187: 268-283
- 45 Studerus E, Kometer M, Hasler F. et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. J Psychopharmacol 2011; 25: 1434-1452
- 46 Hirschfeld T, Schmidt TT. Dose–response relationships of psilocybin-induced subjective experiences in humans. J Psychopharmacol 2021; 0269881121992676 DOI: 10.1177/0269881121992676.
- 47 Dittrich A. Psychological Aspects of Altered States of Consciousness of the LSD Type: Measurements of Their Basic Dimensions and Prediction of Individual Differences. In: Pletscher A, Ladewig D, eds. 50 years of LSD: Current status and perspectives of hallucinogens a symposium the Swiss Academy of Medical Sciences. 1 edn. New York: Parthenon Publishing; 1994: 101-118
- 48 Smigielski L, Kometer M, Scheidegger M. et al. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep 2019; 9: 14914 DOI: 10.1038/s41598-019-50612-3.
- 49 Griffiths RR, Johnson MW, Richards WA. et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol 2018; 32: 49-69 DOI: 10.1177/0269881117731279.
- 50 Hartogsohn I. Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. J Psychopharmacol 2016; 30: 1259-1267 DOI: 10.1177/0269881116677852.
- 51 Kaelen M, Giribaldi B, Raine J. et al. The hidden therapist: Evidence for a central role of music in psychedelic therapy. Psychopharmacology (Berl) 2018; 235: 505-519 DOI: 10.1007/s00213-017-4820-5.
- 52 Kaelen M, Roseman L, Kahan J. et al. LSD modulates music-induced imagery via changes in parahippocampal connectivity. Eur Neuropsychopharmacol 2016; 26: 1099-1109 DOI: 10.1016/j.euroneuro.2016.03.018.
- 53 Strickland JC, Garcia-Romeu A, Johnson MW. Set and setting: A randomized study of different musical genres in supporting psychedelic therapy. ACS Pharmacol Transl Sci 2021; 4: 472-478 DOI: 10.1021/acsptsci.0c00187.
- 54 Haijen E, Kaelen M, Roseman L. et al. Predicting responses to psychedelics: A prospective study. Front Pharmacol 2018; 9: 897 DOI: 10.3389/fphar.2018.00897.
- 55 Terhune DB, Luke DP, Kaelen M. et al. A placebo-controlled investigation of synaesthesia-like experiences under LSD. Neuropsychologia 2016; 88: 28-34 DOI: 10.1016/j.neuropsychologia.2016.04.005.
- 56 Studerus E, Hasler F, Vollenweider FX. The factorial structure of the altered states of consciousness rating scale (OAV). Neuropsychobiology 2009; 70–71
- 57 Hood RW, Morris RJ, Watson PS. Further factor-analysis of Hoods Mysticism Scale. Psychol. Rep 1993; 73: 1176-1178 DOI: 10.2466/pr0.1993.73.3f.1176.
- 58 Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol 2015; 29: 1182-1190 DOI: 10.1177/0269881115609019.
- 59 Hood RW. The construction and preliminary validation of a measure of reported mystical experience. J Sci Stud Relig 1975; 14: 29-41 DOI: 10.2307/1384454.
- 60 Hood RW, Ghorbani N, Watson PJ. et al. Dimensions of the mysticism scale: Confirming the three-factor structure in the United States and Iran. J Sci Stud Relig 2001; 40: 691-705
- 61 Liechti ME, Dolder PC, Schmid Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology (Berl) 2017; 234: 1499-1510 DOI: 10.1007/s00213-016-4453-0.
- 62 Kaelen M, Barrett FS, Roseman L. et al. LSD enhances the emotional response to music. Psychopharmacology (Berl) 2015; 232: 3607-3614 DOI: 10.1007/s00213-015-4014-y.
- 63 Glicksohn J, Barrett TR. Absorption and hallucinatory experience. Appl Cogn Psychol 2003; 17: 833-849 DOI: 10.1002/acp.913.
- 64 Ott U, Reuter M, Hennig J. et al. Evidence for a common biological basis of the absorption trait, hallucinogen effects, and positive symptoms: Epistasis between 5-HT2a and COMT polymorphisms. Am J Med Genet B Neuropsychiatr Genet 2005; 137B: 29-32
- 65 Stenbaek DS, Madsen MK, Ozenne B. et al. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. J Psychopharmacol 2021; 35: 459-468 DOI: 10.1177/0269881120959609.
- 66 Quednow B, Geyer MA, Halberstadt AL. Serotonin and Schizophrenia. In: Müller C, B. J, eds. Handbook of behavioral neurobiology of serotonin. Amsterdam: Elsevier BV; 2010: 585-619 DOI: 10.1016/B978-0-12-374634-4.00034-4
- 67 Griffiths RR, Richards W, Johnson M. et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 2008; 22: 621-632
- 68 MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 2011; 25: 1453-1461 DOI: 10.1177/0269881111420188.
- 69 Smigielski L, Scheidegger M, Kometer M. et al. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage 2019; 196: 207-215 DOI: 10.1016/j.neuroimage.2019.04.009.
- 70 Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 2017; 8: 974 DOI: 10.3389/fphar.2017.00974.
- 71 Griffiths RR, Johnson MW, Carducci MA. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016; 30: 1181-1197 DOI: 10.1177/0269881116675513.
- 72 Ross S, Bossis A, Guss J. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol 2016; 30: 1165-1180 DOI: 10.1177/0269881116675512.
- 73 Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology (Berl) 2018; 235: 535-545 DOI: 10.1007/s00213-017-4733-3.
- 74 Palhano-Fontes F, Barreto D, Onias H. et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychol Med 2019; 49: 655-663 DOI: 10.1017/S0033291718001356.
- 75 Agin-Liebes GI, Malone T, Yalch MM. et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol 2020; 34: 155-166 DOI: 10.1177/0269881119897615.
- 76 Leuner H. Halluzinogene in der psychotherapie. Pharmakopsychiatr Neuropsychopharmakol 1971; 4: 333-351
- 77 Roseman L, Haijen E, Idialu-Ikato K. et al. Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory. J Psychopharmacol 2019; 33: 1076-1087 DOI: 10.1177/0269881119855974.
- 78 Carbonaro TM, Bradstreet MP, Barrett FS. et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol 2016; 30: 1268-1278 DOI: 10.1177/0269881116662634.
- 79 Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 1998; 31: 80-84 DOI: 10.1055/s-2007-979351.
- 80 Lebedev AV, Kaelen M, Lovden M. et al. LSD-induced entropic brain activity predicts subsequent personality change. Hum Brain Mapp 2016; 37: 3203-3213 DOI: 10.1002/hbm.23234.
- 81 Halberstadt AL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res 2015; 277: 99-120
- 82 Halberstadt AL, Chatha M, Klein AK. et al. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology 2020; 167: 107933 DOI: 10.1016/j.neuropharm.2019.107933.
- 83 Kometer M, Cahn BR, Andel D. et al. The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol Psychiatry 2011; 69: 399-406
- 84 Kometer M, Schmidt A, Bachmann R. et al. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry 2012; 72: 898-906 DOI: 10.1016/j.biopsych.2012.04.005.
- 85 Barrett FS, Preller KH, Herdener M. et al. Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. Cereb Cortex 2018; 28: 3939-3950 DOI: 10.1093/cercor/bhx257.
- 86 Kraehenmann R, Pokorny D, Aicher H. et al. LSD increases primary process thinking via serotonin 2A receptor activation. Front Pharmacol 2017; 8: 814 DOI: 10.3389/fphar.2017.00814.
- 87 Valle M, Maqueda AE, Rabella M. et al. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. Eur Neuropsychopharmacol 2016; 26: 1161-1175 DOI: 10.1016/j.euroneuro.2016.03.012.
- 88 Madsen MK, Fisher PM, Burmester D. et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 2019; 44: 1328-1334 DOI: 10.1038/s41386-019-0324-9.
- 89 Pokorny T, Preller KH, Kraehenmann R. et al. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol 2016; 26: 756-766 DOI: 10.1016/j.euroneuro.2016.01.005.
- 90 Strassman RJ. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res 1996; 73: 121-124 DOI: 10.1016/0166-4328(96)00081-2.
- 91 Carter OL, Burr DC, Pettigrew JD. et al. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci 2005; 17: 1497-1508
- 92 Halberstadt AL, Geyer MA. Characterization of the head-twitch response induced by hallucinogens in mice: Detection of the behavior based on the dynamics of head movement. Psychopharmacology (Berl) 2013; 227: 727-739
- 93 De Gregorio D, Comai S, Posa L. et al. d-Lysergic acid diethylamide (LSD) as a model of psychosis: Mechanism of action and pharmacology. Int J Mol Sci 2016; 17 DOI: 10.3390/ijms17111953.
- 94 Gonzalez-Maeso J, Weisstaub NV, Zhou M. et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007; 53: 439-452
- 95 Gonzalez-Maeso J, Ang RL, Yuen T. et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008; 452: 93-97
- 96 Marek GJ. Interactions of hallucinogens with the glutamatergic system: Permissive network effects mediated through cortical layer V pyramidal neurons. Curr Top Behav Neurosci 2018; 36: 107-135 DOI: 10.1007/7854_2017_480.
- 97 Vaidya VA, Marek GJ, Aghajanian GK. et al. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 1997; 17: 2785-2795
- 98 Ly C, Greb AC, Cameron LP. et al. Psychedelics promote structural and functional neural plasticity. Cell Rep 2018; 23: 3170-3182 DOI: 10.1016/j.celrep.2018.05.022.
- 99 Raval NR, Johansen A, Donovan LL. et al. A single dose of psilocybin increases synaptic density and decreases 5-HT(2A) receptor density in the pig brain. Int J Mol Sci 2021; 22: 835 DOI: 10.3390/ijms22020835.
- 100 de la Fuente Revenga M, Zhu B, Guevara C. et al. Prolonged epigenetic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep 2021; 37: 109836 DOI: 10.1101/2021.02.24.432725.
- 101 de la Fuente Revenga M, Shin JM, Vohra HZ. et al. Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo. Sci Rep 2019; 9: 14247 DOI: 10.1038/s41598-019-49913-4.
- 102 Shao LX, Liao C, Gregg I. et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 2021; 109: 2535-2544 e2534 DOI: 10.1016/j.neuron.2021.06.008.
- 103 Hesselgrave N, Troppoli TA, Wulff AB. et al. Harnessing psilocybin: Antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A 2021; 118 DOI: 10.1073/pnas.2022489118.
- 104 Catlow BJ, Song S, Paredes DA. et al. Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 2013; 228: 481-491 DOI: 10.1007/s00221-013-3579-0.
- 105 Berthoux C, Barre A, Bockaert J. et al. Sustained activation of postsynaptic 5-HT2A receptors gates plasticity at prefrontal cortex synapses. Cereb Cortex 2019; 29: 1659-1669 DOI: 10.1093/cercor/bhy064.
- 106 De Gregorio D, Popic J, Enns JP. et al. Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proc Natl Acad Sci U S A 2021; 118 DOI: 10.1073/pnas.2020705118.
- 107 de Almeida RN, Galvao ACM, da Silva FS. et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: Observation from a randomized controlled trial. Front Psychol 2019; 10: 1234 DOI: 10.3389/fpsyg.2019.01234.
- 108 Holze F, Vizeli P, Muller F. et al. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology 2020; 45: 462-471 DOI: 10.1038/s41386-019-0569-3.
- 109 Geyer MA, Vollenweider FX. Serotonin research: Contributions to understanding psychoses. Trends Pharmacol Sci 2008; 29: 445-453
- 110 Alkire MT, Hudetz AG, Tononi G. Consciousness and anesthesia. Science 2008; 322: 876-880
- 111 Ferrarelli F, Massimini M, Sarasso S. et al. Breakdown in cortical effective connectivity during midazolam-induced loss of consciousness. Proc Natl Acad Sci U S A 2010; 107: 2681-2686
- 112 Vollenweider FX, Geyer MA. A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Research Bulletin 2001; 56: 495-507
- 113 Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacol Rev 2019; 71: 316-344 DOI: 10.1124/pr.118.017160.
- 114 Inserra A, De Gregorio D, Gobbi G. Psychedelics in psychiatry: Neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev 2021; 73: 202-277 DOI: 10.1124/pharmrev.120.000056.
- 115 Vollenweider FX, Csomor PA, Knappe B. et al. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 2007; 32: 1876-1887
- 116 Quednow BB, Kometer M, Geyer MA. et al. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology 2012; 37: 630-640
- 117 Riba J, Rodriguez-Fornells A, Barbanoj MJ. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology (Berl) 2002; 165: 18-28 DOI: 10.1007/s00213-002-1237-5.
- 118 Muller F, Lenz C, Dolder P. et al. Increased thalamic resting-state connectivity as a core driver of LSD-induced hallucinations. Acta Psychiatr Scand 2017; 136: 648-657 DOI: 10.1111/acps.12818.
- 119 Preller KH, Burt JB, Ji JL. et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife 2018; 7 DOI: 10.7554/eLife.35082.
- 120 Preller KH, Razi A, Zeidman P. et al. Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proc Natl Acad Sci U S A 2019; 116: 2743-2748 DOI: 10.1073/pnas.1815129116.
- 121 Vollenweider FX, Leenders KL, Scharfetter C. et al. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997; 16: 357-372 DOI: 10.1016/S0893-133X(96)00246-1.
- 122 Gouzoulis-Mayfrank E, Thelen B, Habermeyer E. et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) 1999; 142: 41-50 DOI: 10.1007/s002130050860.
- 123 Vollenweider FX. Advances and pathophysiological models of hallucinogen drug actions in humans: A preamble to schizophrenia research. Pharmacopsychiat 1998; 31: 92-103
- 124 Hermle L, Funfgeld M, Oepen G. et al. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research. Biol Psychiatry 1992; 32: 976-991 DOI: 10.1016/0006-3223(92)90059-9.
- 125 Riba J, Romero S, Grasa E. et al. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl) 2006; 186: 93-98 DOI: 10.1007/s00213-006-0358-7.
- 126 Carhart-Harris RL, Muthukumaraswamy S, Roseman L. et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A 2016; 113: 4853-4858 DOI: 10.1073/pnas.1518377113.
- 127 Carhart-Harris RL, Erritzoe D, Williams T. et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 2012; 109: 2138-2143 DOI: 10.1073/pnas.1119598109.
- 128 Lewis CR, Preller KH, Kraehenmann R. et al. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage 2017; 159: 70-78 DOI: 10.1016/j.neuroimage.2017.07.020.
- 129 Hall H, Farde L, Halldin C. et al. Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907. Synapse 2000; 38: 421-431
- 130 Saulin A, Savli M, Lanzenberger R. Serotonin and molecular neuroimaging in humans using PET. Amino Acids 2012; 42: 2039-2057
- 131 Celada P, Puig MV, Artigas F. Serotonin modulation of cortical neurons and networks. Front Integr Neurosci 2013; 7: 25; 1–20 . https://doi.org/10.3389/fnint.2013.00025
- 132 Llado-Pelfort L, Celada P, Riga MS. et al. Effects of hallucinogens on neuronal activity. Curr Top Behav Neurosci 2018; 36: 75-105 DOI: 10.1007/7854_2017_473.
- 133 Zhang C, Marek GJ. AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 62-71
- 134 Aru J, Suzuki M, Rutiku R. et al. Coupling the state and contents of consciousness. Front Syst Neurosci 2019; 13: 43 DOI: 10.3389/fnsys.2019.00043.
- 135 Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: Rationale and current status of research. CNS Drugs 2013; 27: 703-716
- 136 Llado-Pelfort L, Santana N, Ghisi V. et al. 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. Cereb Cortex 2012; 22: 1487-1497
- 137 Marek GJ, Aghajanian GK. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. J Pharmacol Exp Ther 1996; 278: 1373-1382
- 138 Inserra A, De Gregorio D, Rezai T. et al. Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice. Journal of Psychopharmacology 2021; 0269881121991569 DOI: 10.1177/0269881121991569.
- 139 Lambe EK, Aghajanian GK. Hallucinogen-induced UP states in the brain slice of rat prefrontal cortex: role of glutamate spillover and NR2B-NMDA receptors. Neuropsychopharmacology 2006; 31: 1682-1689
- 140 Martin-Ruiz R, Puig MV, Celada P. et al. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 2001; 21: 9856-9866
- 141 Puig MV, Celada P, az-Mataix L. et al. In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: Relationship to thalamocortical afferents. Cereb Cortex 2003; 13: 870-882
- 142 Barre A, Berthoux C, De BD. et al. Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning. Proc Natl Acad Sci U S A 2016; 113: E1382-E1391
- 143 Larkum ME, Zhu JJ, Sakmann B. A new cellular mechanism for coupling inputs arriving at different cortical layers. Nature 1999; 398: 338-341 DOI: 10.1038/18686.
- 144 Burt JB, Preller KH, Demirtas M. et al. Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD. Elife 2021; 10 DOI: ARTN e6932010.7554/eLife.69320
- 145 Ji JLS, Helmer M, Fonteneau C. et al. Mapping brain-behavior space relationships along the psychosis spectrum. Elife 2021; 10 DOI: ARTN e6696810.7554/eLife.66968
- 146 Farzan F, Vernet M, Shafi MM. et al. Characterizing and modulating brain circuitry through transcranial magnetic stimulation combined with electroencephalography. Front Neural Circuits 2016; 10: 73 DOI: 10.3389/fncir.2016.00073.
- 147 Tremblay S, Rogasch NC, Premoli I. et al. Clinical utility and prospective of TMS-EEG. Clin Neurophysiol 2019; 130: 802-844 DOI: 10.1016/j.clinph.2019.01.001.
- 148 Carhart-Harris RL, Leech R, Hellyer PJ. et al. The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 2014; 8: 20 DOI: 10.3389/fnhum.2014.00020.
- 149 Carhart-Harris RL. The entropic brain - revisited. Neuropharmacology 2018; 142: 167-178 DOI: 10.1016/j.neuropharm.2018.03.010.
- 150 Schartner MM, Carhart-Harris RL, Barrett AB. et al. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Sci Rep 2017; 7: 46421 DOI: 10.1038/srep46421.
- 151 Timmermann C, Roseman L, Schartner M. et al. Neural correlates of the DMT experience assessed with multivariate EEG. Sci Rep 2019; 9: 16324 DOI: 10.1038/s41598-019-51974-4.
- 152 Atasoy S, Roseman L, Kaelen M. et al. Connectome-harmonic decomposition of human brain activity reveals dynamical repertoire re-organization under LSD. Sci Rep 2017; 7: 17661 DOI: 10.1038/s41598-017-17546-0.
- 153 Viol A, Palhano-Fontes F, Onias H. et al. Shannon entropy of brain functional complex networks under the influence of the psychedelic Ayahuasca. Sci Rep 2017; 7: 7388 DOI: 10.1038/s41598-017-06854-0.
- 154 Herzog R, Mediano PAM, Rosas FE. et al. A mechanistic model of the neural entropy increase elicited by psychedelic drugs. Sci Rep 2020; 10: 17725 DOI: 10.1038/s41598-020-74060-6.
- 155 Timmermann C, Spriggs MJ, Kaelen M. et al. LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm. Neuropharmacology 2018; 142: 251-262 DOI: 10.1016/j.neuropharm.2017.10.039.
- 156 Umbricht D, Vollenweider FX, Schmid L. et al. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: Implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology 2003; 28: 170-181
- 157 Schmidt A, Bachmann R, Kometer M. et al. Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. Neuropsychopharmacology 2012; 37: 865-875
- 158 Bravermanova A, Viktorinova M, Tyls F. et al. Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers. Psychopharmacology (Berl) 2018; 235: 491-503 DOI: 10.1007/s00213-017-4807-2.
- 159 Heekeren K, Daumann J, Neukirch A. et al. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berl) 2008; 199: 77-88
- 160 Duerler P, Brem S, Fraga-Gonzalez G. et al. Psilocybin induces aberrant prediction error processing of tactile mismatch responses-a simultaneous EEG-FMRI study. Cereb Cortex 2021; DOI: 10.1093/cercor/bhab202.
- 161 Grasso M, Albantakis L, Lang JP. et al. Causal reductionism and causal structures. Nat Neurosci 2021; 24: 1348-1355 DOI: 10.1038/s41593-021-00911-8.
- 162 Friston K. The free-energy principle: A unified brain theory?. Nat Rev Neurosci 2010; 11: 127-138
- 163 Keller GB, Mrsic-Flogel TD. Predictive processing: A canonical cortical computation. Neuron 2018; 100: 424-435 DOI: 10.1016/j.neuron.2018.10.003.
- 164 Muller F, Dolder PC, Schmidt A. et al. Altered network hub connectivity after acute LSD administration. Neuroimage Clin 2018; 18: 694-701 DOI: 10.1016/j.nicl.2018.03.005.
- 165 Carhart-Harris RL, Leech R, Erritzoe D. et al. Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull 2013; 39: 1343-1351 DOI: 10.1093/schbul/sbs117.
- 166 Roseman L, Leech R, Feilding A. et al. The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front Hum Neurosci 2014; 8: 204
- 167 Palhano-Fontes F, Andrade KC, Tofoli LF. et al. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One 2015; 10: e0118143 DOI: 10.1371/journal.pone.0118143.
- 168 Muller F, Liechti ME, Lang UE. et al. Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain. Prog Brain Res 2018; 242: 159-177 DOI: 10.1016/bs.pbr.2018.08.004.
- 169 Preller KH, Duerler P, Burt JB. et al. Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry 2020; DOI: 10.1016/j.biopsych.2019.12.027.
- 170 Raichle ME. The brain's default mode network. Annu Rev Neurosci 2015; 38: 433-447 DOI: 10.1146/annurev-neuro-071013-014030.
- 171 Lord LD, Expert P, Atasoy S. et al. Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. Neuroimage 2019; 199: 127-142 DOI: 10.1016/j.neuroimage.2019.05.060.
- 172 Tagliazucchi E, Roseman L, Kaelen M. et al. Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol 2016; 26: 1043-1050 DOI: 10.1016/j.cub.2016.02.010.
- 173 Murphy K, Fox MD. Towards a consensus regarding global signal regression for resting state functional connectivity MRI. Neuroimage 2017; 154: 169-173 DOI: 10.1016/j.neuroimage.2016.11.052.
- 174 Deco G, Cruzat J, Cabral J. et al. Whole-brain multimodal neuroimaging model using serotonin receptor maps explains non-linear functional effects of LSD. Curr Biol 2018; 28: 3065-3074 e3066 DOI: 10.1016/j.cub.2018.07.083.
- 175 Barrett FS, Krimmel SR, Griffiths R. et al. Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. Neuroimage 2020; 116980 DOI: 10.1016/j.neuroimage.2020.116980.
- 176 Grandjean J, Buehlmann D, Buerge M. et al. Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. Neuroimage 2021; 225: 117456 DOI: 10.1016/j.neuroimage.2020.117456.
- 177 Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ. et al. Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci 2013; 33: 15171-15183
- 178 Qin P, Northoff G. How is our self related to midline regions and the default-mode network?. Neuroimage 2011; 57: 1221-1233
- 179 Klaassens BL, van Gorsel HC, Khalili-Mahani N. et al. Single-dose serotonergic stimulation shows widespread effects on functional brain connectivity. Neuroimage 2015; 122: 440-450 DOI: 10.1016/j.neuroimage.2015.08.012.
- 180 Muller F, Holze F, Dolder P. et al. MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens. Neuropsychopharmacology 2020; DOI: 10.1038/s41386-020-00906-2.
- 181 Garrison KA, Zeffiro TA, Scheinost D. et al. Meditation leads to reduced default mode network activity beyond an active task. Cogn Affect Behav Neurosci 2015; 15: 712-720 DOI: 10.3758/s13415-015-0358-3.
- 182 Elton A, Gao W. Task-positive functional connectivity of the default mode network transcends task domain. J Cogn Neurosci 2015; 27: 2369-2381 DOI: 10.1162/jocn_a_00859.
- 183 Steriade M. Grouping of brain rhythms in corticothalamic systems. Neuroscience 2006; 137: 1087-1106 DOI: 10.1016/j.neuroscience.2005.10.029.
- 184 Uhlhaas PJ, Linden DE, Singer W. et al. Dysfunctional long-range coordination of neural activity during Gestalt perception in schizophrenia. J Neurosci 2006; 26: 8168-8175
- 185 Lopes da Silva F. EEG and MEG: Relevance to neuroscience. Neuron 2013; 80: 1112-1128
- 186 Kometer M, Pokorny T, Seifritz E. et al. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology (Berl) 2015; 232: 3663-3676
- 187 Riba J, Anderer P, Morte A. et al. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Br J Clin Pharmacol 2002; 53: 613-628 DOI: 10.1046/j.1365-2125.2002.01609.x.
- 188 Riba J, Anderer P, Jane F. et al. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: A functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology 2004; 50: 89-101 DOI: 10.1159/000077946.
- 189 Schenberg EE, Alexandre JF, Filev R. et al. Acute biphasic effects of ayahuasca. PLoS One 2015; 10: e0137202 DOI: 10.1371/journal.pone.0137202.
- 190 Buschman TJ, Denovellis EL, Diogo C. et al. Synchronous oscillatory neural ensembles for rules in the prefrontal cortex. Neuron 2012; 76: 838-846 DOI: 10.1016/j.neuron.2012.09.029.
- 191 Başar E. A review of gamma oscillations in healthy subjects and in cognitive impairment. International Journal of Psychophysiology 2013; 90: 99-117 DOI: 10.1016/j.ijpsycho.2013.07.005.
- 192 Fries P. Neuronal gamma-band synchronization as a fundamental process in cortical computation. Annu Rev Neurosci 2009; 32: 209-224 DOI: 10.1146/annurev.neuro.051508.135603.
- 193 Griffiths BJ, Parish G, Roux F. et al. Directional coupling of slow and fast hippocampal gamma with neocortical alpha/beta oscillations in human episodic memory. Proc Natl Acad Sci U S A 2019; 116: 21834-21842 DOI: 10.1073/pnas.1914180116.
- 194 Vinck M, Bosman CA. More gamma more predictions: Gamma-synchronization as a key mechanism for efficient integration of classical receptive field inputs with surround predictions. Front Syst Neurosci 2016; 10: 35 DOI: 10.3389/fnsys.2016.00035.
- 195 Honkanen R, Rouhinen S, Wang S. et al. Gamma oscillations underlie the maintenance of feature-specific information and the contents of visual working memory. Cerebral cortex (New York, NY: 1991) 2014; 25 DOI: 10.1093/cercor/bhu263.
- 196 Eisner BG, Cohen S. Psychotherapy with lysergic acid diethylamide. J Nerv Ment Dis 1958; 127: 528-539 DOI: 10.1097/00005053-195812000-00006.
- 197 Klee GD. Lysergic acid diethylamide (LSD-25) and ego functions. Arch Gen Psychiatry 1963; 8: 461-474 DOI: 10.1001/archpsyc.1963.01720110037005.
- 198 Leuner H. Psycholytic therapy: Clinical psychotherapy with adjuvant LSD-25 and related substances. Z Psychother Med Psychol 1963; 13: 57-64
- 199 Hermle L, Kraehenmann R. Experimental psychosis research and schizophrenia-similarities and dissimilarities in psychopathology. Curr Top Behav Neurosci 2017; DOI: 10.1007/7854_2016_460.
- 200 Vollenweider FX. Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci 2001; 3: 265-279
- 201 Preller KH, Pokorny T, Hock A. et al. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci U S A 2016; 113: 5119-5124 DOI: 10.1073/pnas.1524187113.
- 202 Lebedev AV, Lovden M, Rosenthal G. et al. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Hum Brain Mapp 2015; 36: 3137-3153 DOI: 10.1002/hbm.22833.
- 203 Luppi AI, Carhart-Harris RL, Roseman L. et al. LSD alters dynamic integration and segregation in the human brain. Neuroimage 2021; 227: 117653 DOI: 10.1016/j.neuroimage.2020.117653.
- 204 Northoff G, Boeker H, Bogerts B. Subjective experience and neuronal integration in the brain: Do we need a first-person neuroscience?. Fortschr Neurol Psychiatr 2006; 74: 627-634
- 205 Damasio AR. How the brain creates the mind. Sci Am 1999; 281: 112-117 DOI: 10.1038/scientificamerican1299-112.
- 206 Araujo HF, Kaplan J, Damasio A. Cortical midline structures and autobiographical-self processes: An activation-likelihood estimation meta-analysis. Front Hum Neurosci 2013; 7: 548 DOI: 10.3389/fnhum.2013.00548.
- 207 Northoff G, Bermpohl F. Cortical midline structures and the self. Trends Cogn Sci 2004; 8: 102-107 DOI: 10.1016/j.tics.2004.01.004.
- 208 Metzinger T. Self-modeling epistemic spaces and the contraction principle. Cogn Neuropsychol 2020; 37: 197-201 DOI: 10.1080/02643294.2020.1729110.
- 209 Smigielski L, Kometer M, Scheidegger M. et al. P300-mediated modulations in self-other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the self-other overlap. Hum Brain Mapp 2020; 1-15 DOI: 10.1002/hbm.25174.
- 210 Rauss K, Pourtois G. What is bottom-up and what is top-down in predictive coding?. Front Psychol 2013; 4: 276 DOI: 10.3389/fpsyg.2013.00276.
- 211 Ho JT, Preller KH, Lenggenhager B. Neuropharmacological modulation of the aberrant bodily self through psychedelics. Neurosci Biobehav Rev 2020; 108: 526-541 DOI: 10.1016/j.neubiorev.2019.12.006.
- 212 Weber LA, Diaconescu AO, Mathys C. et al. Ketamine affects prediction errors about statistical regularities: A computational single-trial analysis of the mismatch negativity. J Neurosci 2020; 40: 5658-5668 DOI: 10.1523/JNEUROSCI.3069-19.2020.
- 213 Hood RW, Streib H. “Fuzziness” or semantic diversification? Insights about the semantics of “Spirituality” in cross-cultural comparison (Conclusion). In: Streib H, Hood JRW, eds. Semantics and Psychology of Spirituality: A Cross-Cultural Analysis. Cham: Springer International Publishing; 2016: 153-161 DOI: 10.1007/978-3-319-21245-6_10
- 214 Keller B, Klein C, Swhajor-Biesemann A. et al. The semantics of 'Spirituality’ and related self-identifications: A comparative study in Germany and the USA. Arch Psychol Relig 2013; 35: 71-100 DOI: 10.1163/15736121-12341254.
- 215 Roseman L, Demetriou L, Wall MB. et al. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology 2018; 142: 263-269 DOI: 10.1016/j.neuropharm.2017.12.041.
- 216 Marrazzi AS, Meisch RA, Pew WL. et al. Quantified LSD effects on ego strength. Recent Adv Biol Psychiatry 1966; 9: 197-207 DOI: 10.1007/978-1-4684-8228-7_14.
- 217 Vago DR, Silbersweig DA. Self-awareness, self-regulation, and self-transcendence (S-ART): A framework for understanding the neurobiological mechanisms of mindfulness. Front Hum Neurosci 2012; 6: 296 DOI: 10.3389/fnhum.2012.00296.
- 218 Dahl CJ, Lutz A, Davidson RJ. Reconstructing and deconstructing the self: Cognitive mechanisms in meditation practice. Trends Cogn Sci 2015; 19: 515-523 DOI: 10.1016/j.tics.2015.07.001.
- 219 Bernstein A, Hadash Y, Lichtash Y. et al. Decentering and related constructs: A critical review and metacognitive processes model. Perspect Psychol Sci 2015; 10: 599-617 DOI: 10.1177/1745691615594577.
- 220 Kessel R, Gecht J, Forkmann T. et al. Exploring the relationship of decentering to health related concepts and cognitive and metacognitive processes in a student sample. BMC Psychol 2016; 4: 11 DOI: 10.1186/s40359-016-0115-6.
- 221 Grimm S, Ernst J, Boesiger P. et al. Reduced negative BOLD responses in the default-mode network and increased self-focus in depression. World J Biol Psychiatry 2011; 12: 627-637
- 222 Pokorny T, Preller KH, Kometer M. et al. Effect of psilocybin on empathy and moral decision-making. Int J Neuropsychopharmacol 2017; 20: 747-757 DOI: 10.1093/ijnp/pyx047.
- 223 Dolder PC, Schmid Y, Muller F. et al. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology 2016; 41: 2638-2646 DOI: 10.1038/npp.2016.82.
- 224 Duerler P, Schilbach L, Stampfli P. et al. LSD-induced increases in social adaptation to opinions similar to one’s own are associated with stimulation of serotonin receptors. Sci Rep 2020; 10: 12181 DOI: 10.1038/s41598-020-68899-y.
- 225 Bershad AK, Schepers ST, Bremmer MP. et al. Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry 2019; 86: 792-800 DOI: 10.1016/j.biopsych.2019.05.019.
- 226 Schmidt A, Kometer M, Bachmann R. et al. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology (Berl) 2013; 225: 227-239
- 227 Mueller F, Lenz C, Dolder PC. et al. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry 2017; 7: e1084 DOI: 10.1038/tp.2017.54.
- 228 Kraehenmann R, Preller KH, Scheidegger M. et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry 2015; 78: 572-581
- 229 Kraehenmann R, Schmidt A, Friston K. et al. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage Clin 2016; 11: 53-60
- 230 Grimm O, Kraehenmann R, Preller KH. et al. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. Eur Neuropsychopharmacol 2018; 28: 691-700 DOI: 10.1016/j.euroneuro.2018.03.016.
- 231 Barrett FS, Doss MK, Sepeda ND. et al. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep 2020; 10: 2214 DOI: 10.1038/s41598-020-59282-y.
- 232 Mertens LJ, Wall MB, Roseman L. et al. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol 2020; 34: 167-180 DOI: 10.1177/0269881119895520.